Levofloxacin in the Management of Lower Respiratory Tract Infections
Due to Common Pathogens
Michael P. Habib, MD, CM
Professor of Clinical Medicine, Arizona Respiratory Center, University of Arizona, Tucson, AZ, USA
Levofloxacin, the l- isomer of ofloxacin, has gained widespread use and acceptance for the treatment of lower respiratory tract infections (LRTIs), including acute exacerbations of chronic bronchitis and community-acquired pneumonia. One of the earliest "respiratory" quinolones to be marketed, levofloxacin was approved for use in the United States in 1997. Since
the very first introduction in Japan in 1993, worldwide, more than 250 million prescriptions for this medication have been written and the overall safety profile has been excellent. This review will focus on the use of levofloxacin in the management of these LRTIs, emphasizing its clinical utility in treating the common microorganisms associated with them.